KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals International PLC - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Kiniksa Pharmaceuticals International PLC - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of July 24, 2026, KNSA stock price declined to $62.84 with 596,034 million shares trading.

KNSA has a beta of -0.43, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.01 to the broad based SPY ETF.

KNSA has a market cap of $4.83 billion. This is considered a Mid Cap stock.

Last quarter Kiniksa Pharmaceuticals International PLC - Class A reported $214 million in Revenue and $.27 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.11.

In the last 3 years, KNSA traded as high as $67.53 and as low as $14.12.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): VTI, IWM, VB, VBK, IWO.

KNSA has outperformed the market in the last year with a price return of +133.6% while the SPY ETF gained +17.7%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +46.9% and -0.9%, respectively, while the SPY returned +3.8% and -2.1%, respectively.

KNSA support price is $61.13 and resistance is $64.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.